A pivotal Phase III trial of GMI-1271 in Patients With Acute Myeloid Leukemia.

Trial Profile

A pivotal Phase III trial of GMI-1271 in Patients With Acute Myeloid Leukemia.

Planning
Phase of Trial: Phase III

Latest Information Update: 30 May 2018

At a glance

  • Drugs Uproleselan-sodium (Primary) ; Cytarabine; Etoposide; Fludarabine; Idarubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 30 May 2018 According to a GlycoMimetics media release, trial is led by Geoffrey Uy, M.D., Associate Professor of Medicine, Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis.
    • 30 May 2018 According to a GlycoMimetics media release, company announced it had signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under the terms of the CRADA, GlycoMimetics will collaborate with both the NCI and the Alliance for Clinical Trials.
    • 03 May 2018 According to a GlycoMimetics media release, based on guidance from the US Food and Drug Administration company announced study design for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top